Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 271

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 271
---
, 2023, 597 common shares with a fair value of $10,000 were issued to providers of investor services in respect of services. |

| (vii) | On August 28, 2023, 585 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $65,143 at the time of issuance and 44 common shares with a fair value of $607 were issued to providers of investor services in respect of services. |

| (viii) | On September 18, 2023, the Company completed an underwritten public offering of 225,833 common shares at a price to the public of $9.00 per share and pre-funded warrants to purchase 24,167 common shares at a price to the public of $8.97 per pre-funded warrant (“Pre-Funded Warrants”), for aggregate gross proceeds of $2.25 million (the “September 2023 Public Offering”). The Pre-Funded Warrants were exercisable at $0.03 into one common share, and all the Pre-Funded Warrants were exercised by September 30, 2023. In addition, each September 2023 Public Offering shareholder and each Pre-Funded Warrant holder received a common warrant, which was immediately exercisable, will expire five years from the date of issuance and have an exercise price of $9.00 per common share (“September 2023 Public Offering Warrant”). The September 2023 Public Offering warrants include a cashless exercise provision and repricing provisions under certain circumstances that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. Net proceeds from the offering were $1,814,193. |

| (ix) | During the period between October 17, 2023 and October 20, 2023, 784,584 April 2023 Warrants with a fair value of $574,040 were exercised into 119,433 common shares. |

F-26 CLEARMIND MEDICINE INC. Notes to the Consolidated Financial Statements (Expressed in United States Dollars)

| 8. | Share               
 Capital (continued) |

| (i) | On November 26, 2021, the Company issued 44 common shares with a fair value of $21,100 to the Chief Science Officer (“CSO”) of the Company. |

| (ii) | On